BJMO - volume 8, issue 5, november 2014
L. Decoster MD, PhD
The 2014 annual meeting of the European Society for Medical Oncology (ESMO) featured a number of interesting studies in endocrine and neuroendocrine oncology. This report will first focus on two presentations regarding lenvatinib in the treatment of thyroid cancers. In addition to this, the final OS of the RADIANT-3 study, evaluating everolimus in patients with advanced pancreatic neuroendocrine tumours (NET), will be summarized. The last part of the report will focus on the molecular profiling of NETs and discusses a study assessing the quality of life in NET patients using lanreotide autogel.
(BELG J MED ONCOL 2014;8(4):163–5)
Read moreBJMO - volume 8, issue 5, november 2014
H. Wildiers MD, PhD, Tom Feys MBA, MSc
(BELG J MED ONCOL 2014;8(4):166–70)
Read moreBJMO - volume 8, issue 5, november 2014
B. Neyns MD, PhD
(BELG J MED ONCOL 2014;8(4):171–6)
Read moreBJMO - volume 8, issue 5, november 2014
J. De Grève MD, PhD
(BELG J MED ONCOL 2014;8(4):177–9)
Read moreBJMO - volume 8, issue 5, november 2014
P. Specenier MD, PhD
This report will discuss the key lectures on head and neck cancer (HNC) presented during the 2014 annual meeting of the European Society for Medical Oncology. After addressing the novelties in immunotherapeutic therapy for HNC, the top stories on news promising drugs will be discussed. In addition some presentations discussing the set up and implementation of practice guidelines in HNC will be addressed to end of with some innovations on biomarkers.
(BELG J MED ONCOL 2014;8(4):180–3)
Read moreBJMO - volume 8, issue 5, december 2014
T. Vermassen PhD, J. M. Kerst MD, PhD, B. Tombal MD, PhD, S. Rottey MD, PhD
The Belgian multidisciplinary meeting on urological cancers was initiated as the first national multidisciplinary scientific meeting of medical oncologists (BSMO), urologists (BAU) and radiotherapists (ABRO-BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of uro-oncology.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (BSMO); L. Hoekx, S. Joniau, T. Roumeguere (BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (ABRO-BVRO). The first meeting, held in Brussels on March 29th, 2014 was a great success with more than 150 attendees of the different specialisations involved.
(BELG J MED ONCOL 2014;8(5):224–7)
Read moreBJMO - volume 8, issue 3, july 2014
Tom Feys MBA, MSc, MBA
(BELG J MED ONCOL 2014;8(3):98–100)
Read more
Top
